China biotech outlicensing tops US$52 billion in first 2 months after global deal surge

South China Morning PostEN 1 min read 100% complete by Julie ZhangMarch 4, 2026 at 10:30 AM

AI Summary

short article 1 min

Chinese biotech outlicensing deals have surged in the first two months of 2024, exceeding $52 billion across 41 transactions, following a record-breaking 2023. This increase signifies China's growing importance as a source of innovative drug candidates for multinational pharmaceutical companies. Recent deals include Sino Biopharmaceutical's $1.53 billion agreement with Sanofi and Antengene Corporation's $1.18 billion deal with UCB. These cross-border transactions highlight a shift towards long-term partnerships, driven by global companies seeking novel therapies. The market is watching for potential government support for drug development as China's "two sessions" begin.

Key Entities & Roles

Key Player Opposition Context

Belgium 40% JPMorgan Chase 50% France ×250% Chia Tai Tianqing Pharmaceutical 60% Yang Huang 60% Antengene Corporation 70% UCB 70% Sanofi ×380% Sino Biopharmaceutical ×280% China ×590%

Keywords

outlicensing deals 100% china biotech 90% pharmaceutical companies 70% drug development 60% drug candidates 50% cross-border transactions 50% sanofi 40% sino biopharmaceutical 40%